University of South Carolina

TAMPA, Fla., Sept. 12, 2024 /PRNewswire/ -- Probo Medical ("Probo"), a global diagnostic imaging solutions provider, has announced the appointment of Michael Asmer as Chairman of the Board and Greg Kopulos as Chief Executive Officer of Probo. Michael Asmer was formerly Chief Executive Officer of Probo and, prior to Probo, was the founder and Chief Executive Officer of MedCorp, which was acquired by Probo in 2018. Prior to MedCorp, Asmer held various leadership roles at Physician Sales and Service (PSS), prior to its acquisition by McKesson, and also at Henry Schein. Asmer earned his Bachelor's degree from the University of South Carolina. "I am tremendously proud of what our team has accomplished over the last five years at Probo and am also excited for what lies ahead," stated Asmer. "With the integration of recent acquisitions, Probo enters a new phase of growth where we can support our customers with a comprehensive offering of diagnostic imaging solutions." Greg Kopulos joined Probo in 2024 from Chartis, a healthcare consulting firm where he was President of their Clinical Quality Solutions business. Prior to that, he spent 20 years at GE Healthcare where among other roles, he was Chief Operating Officer of Global Service, Chief Operating Officer of US & Canada as well as the Senior Vice President of Strategy. Kopulos earned his Masters of Business Administration from Marquette University and his Bachelor's degree from University of Wisconsin-Whitewater. "Probo is well on its way to becoming a global leader in diagnostic imaging solutions. I am humbled and excited to build on the great work of Michael and the entire Probo team," remarked Kopulos. "With the continued investment in and integration of our prior acquisitions, Probo has never been better positioned to help our customers deliver quality care to their patients while providing needed cost savings." Probo Medical is backed by Avista Healthcare Partners, a leading private equity firm focused exclusively on healthcare with over $8 billion invested in more than 45 growth-oriented healthcare businesses globally. About Probo Medical Probo Medical is a global diversified solutions provider of diagnostic imaging products and services, including equipment sales, service, rental, repair and installation. For more information about Probo Medical, visit . Contacts For Probo Medical: Contact: Adam Walter, Probo Medical Email: [email protected] For Avista Healthcare Partners: Daniel Yunger / William Halliday Kekst CNC [email protected] / [email protected] SOURCE Probo Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure’s Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company’s next CEO. Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served as CEO since 2002, will serve as Senior Advisor into early 2026, and will continue to serve on Novocure’s Board of Directors. These changes will become effective on January 1, 2025. “It has been a special honor and one of the greatest privileges of my life to serve as Novocure’s CEO for the last 22 years,” said Mr. Danziger. “I am very proud of the organization we have built starting with just a few people in a preclinical lab to where we stand today – treating thousands of patients living with aggressive forms of cancer. Now, we are poised to expand the potential of Tumor Treating Fields therapy to many more people. I am confident that under Ashley’s leadership Novocure is well positioned to achieve great things.” “Under Asaf’s leadership, Novocure has grown from its earliest days as a start-up into the successful, global company we see today. Our patient-forward mission is a manifestation of Asaf’s vision,” said William Doyle, Executive Chairman, Novocure. “On behalf of Novocure’s Board of Directors, we are grateful for all of Asaf’s many accomplishments and are excited to welcome Ashley as our next CEO. Ashley’s strategic vision, commitment to our mission, and proven track record of operational excellence position her perfectly to drive Novocure’s next stage of growth.” “It has been a professional and personal highlight for me to work hand in hand with Asaf over the past 10 years and I am grateful for his leadership and partnership,” said Ms. Cordova. “Novocure’s mission to extend survival in aggressive forms of cancer is as significant today as it was 20 years ago, and I am excited to take on the role of CEO at this pivotal time as we look to expand the reach of Tumor Treating Fields therapy across multiple solid tumor indications.” The company also announced today that Wilco Groenhuysen will step down as Chief Operating Officer (COO) effective October 1, 2024. Mukund Paravasthu, who joined Novocure in 2020 and currently holds the position of Senior Vice President, Product Development, will expand his current responsibilities and transition into the role of COO. “I would like to personally thank Wilco for his friendship, dedication, and leadership over the last 12 years,” said Mr. Danziger. “Wilco helped shape and build our financial, back office and operations functions, and I am grateful for the enduring impact he made at Novocure.” About Asaf Danziger Asaf Danziger has served as Novocure’s Chief Executive Officer since 2002 and has been a member of the Board of Directors since 2012. Mr. Danziger was Novocure’s fourth employee, leading the organization from its preclinical development stage through regulatory approvals and product commercialization, growing Novocure into an organization with over $500 million in annual global sales and more than 1,500 employees. Mr. Danziger holds a Bachelor of Science in material engineering from Ben-Gurion University of the Negev, Israel. About Ashley Cordova Ashley Cordova has served as Novocure’s Chief Financial Officer since September 2020. She is responsible for global oversight of Novocure’s revenue and financial operations, including reimbursement activities, financial reporting, financial planning and analysis, treasury, tax, and investor relations. Joining Novocure in 2014, Ms. Cordova is a leader who combines strategic vision with emphasis on consistent operational excellence. Throughout her tenure, Ms. Cordova has been integral to building Novocure’s global organization and preparing the company for its next stage of growth. She is a visible and engaged enterprise leader, committed to Novocure’s patient-forward mission. Prior to joining Novocure, Ms. Cordova served in various financial roles at Zoetis Inc. from 2012 to 2014 and Pfizer Inc. from 2005 to 2012. Ms. Cordova graduated with a bachelor’s degree in music and business from Furman University and earned her International Master of Business Administration from the University of South Carolina. Ms. Cordova currently serves on the Board of Directors of Therabody, Inc. About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and X (Twitter). Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion. Investors: Ingrid Goldberg investorinfo@novocure.com Media: Catherine Falcetti media@novocure.com Source: Novocure

Tampa General and University of South Florida Announce Agreement to Strengthen Affiliation, with Greater Investments in Talent, GME Programs, Academics and Research. TAMPA, Fla., Aug. 27, 2024 /PRNewswire/ -- Tampa General Hospital (TGH) and the USF Health Morsani College of Medicine (USF Health) at the University of South Florida (USF) announced today a historic investment in academic medicine, strengthening integration across the two organizations and deepening their commitment to excellence in quality health care. Tampa General will direct more than $162 million in 2025 to USF Health, roughly $100 million more than what TGH invested in its university affiliate just over 5 years ago. The extraordinary investment supports a shared vision between the two affiliated organizations to increase integration, recruit best-in-class providers and advance research initiatives while continuing to grow the region's economy and create jobs. "Through our collaborative efforts at Tampa General and USF Health, we are transforming the health care landscape. Together, we have expanded our world-class teams, launched new cutting-edge initiatives, adopted innovative technologies and disrupted old care delivery models," said John Couris, president and CEO and Tampa General Hospital. "We're setting the standard for the future of health care, and now is the time to strengthen our investments and integrations across the academic health system so that we can have an even more meaningful impact on our patients and the health care industry across our state and the country." "The University of South Florida's long-standing partnership with Tampa General Hospital has provided significant benefits to our students and our region, and today's approval propels us even further along in our collaboration," said USF President Rhea Law. "At the core of this agreement lies our commitment to delivering world-class patient care, expanding our state's health care workforce and advancing research — three goals that play a vital role in the future of our university and our communities." "This agreement is evidence of what we've long known to be true – that USF Health and Tampa General are stronger together than we could ever be apart," said Dr. Charles J. Lockwood, executive vice president of USF Health and dean of the USF Health Morsani College of Medicine. "Our expanded union will certainly advance both of our institutions but, more importantly, it will also benefit our patients and the greater community as we advance quality health care." The commitment comes in the form of a revised affiliation agreement, which was approved by the board of directors at Tampa General on August 6 and approved today by the Governance Committee acting on behalf of the USF Board of Trustees. The agreement is effective October 1. "As we continue to deepen our relationship with USF Health, together we are fundamentally transforming the health care landscape in Florida. We're attracting new talent, expanding our health care workforce, discovering new treatments and therapies and saving more lives," said Drew Graham, chair of the board of directors at Tampa General. "With this increased investment and enhanced integration, we are building the academic health system of the future to promote health and wellness for families, and provide world-class care to the patients we serve." "This is an exciting time at USF and for the entire Tampa Bay area, with tremendous growth and opportunity," said Will Weatherford, chair of the USF Board of Trustees and chair of the BOT Governance Committee. "Our expanded connection to Tampa General adds incredible value to that continued progress and we certainly look forward to seeing the expanded affiliation further elevate our region." Tampa General Hospital and USF Health form one of the nation's leading academic health systems. Tampa General and USF Health combine clinical care, teaching and research to deliver the best possible outcomes and support patients, including those with the most severe illnesses and complex health conditions. Tampa General has been affiliated with USF Health since the medical school was established more than five decades ago. Over the years, the partnership has evolved, enabling both organizations to work more collaboratively to advance patient care, improve outcomes and propel breakthroughs. Leveraging their collective assets and expertise, the system has impacted the lives of millions of patients, as well as attracted some of the world's most sought-after specialists, deployed next generation technology and advanced cutting-edge research. Through the joint Office of Clinical Research and the Center of Research Excellence, the system fosters research and development with support for administrative services, clinical trials and journal submissions. By collaborating on joint clinical trials and translational studies, the system takes discoveries from the laboratory bench to the patient bedside, bringing the most sophisticated level of care to the community and beyond. The academic health system is educating and training the next generation of health care providers and workforce to expand access to the exceptional care provided at Tampa General. Several hundred USF Health medical students conduct clinical rotations each year at Tampa General, along with 726 residents and fellows who also train there. Tampa General funds programs that support 344 of these USF residents, as well as more than 70 training programs. On average, every month, there are nearly 200 undergrad USF nursing students and 315 ancillary USF students gaining hands-on experience at Tampa General Hospital. Working together, Tampa General and USF Health have earned national recognition in research and quality of care. The academic health system climbed to the second highest ranked hospital in Florida this year, according to U.S. News and World Report's 2024-2025 Best Hospitals, and Tampa General is recognized as one of the nation's top 50 hospitals in eight medical specialties and ranks among the top 10% in three additional medical specialties. In 2023, USF joined the nation's leading research institutions as a member of the prestigious Association of American Universities, in part because of the university's commitment to research and innovation in health care. The growing prominence of the academic health system has attracted new investments and talent to the area, developing Tampa's growing reputation as a global destination for exceptional care, advanced research and emerging biotechnology. The academic, research, science and technology organizations reside within the Tampa Medical and Research District, which is anchored by TGH and USF Health. Looking ahead, Tampa General and USF Health are on a journey to transform the health care landscape by pursuing innovative ways to disrupt the traditional delivery models and lead to better patient outcomes. ABOUT TAMPA GENERAL HOSPITAL Tampa General Hospital, a 981-bed, not-for-profit, academic health system, is one of the largest hospitals in America and delivers world-class care as the region's only center for Level l trauma and comprehensive burn care. Tampa General Hospital is the highest-ranked hospital in the market in U.S. News & World Report's 2024-2025 Best Hospitals, with two medical specialties ranking among the top 20 in the nation and eight medical specialties ranking among the top 50 best hospital programs in the United States. Tampa General Hospital has been designated as a model of excellence by the 2022 Fortune/Merative 100 Top Hospitals list. The academic health system's commitment to growing and developing its team members is recognized by three prestigious Forbes magazine rankings – in the top 100 nationally in the 2024 America's Best Large Employers, the top 50 in Florida in the 2024 America's Best Employer's by State and the 2023 America's Best Employers for Women, Tampa General is the safety net hospital for the region, caring for everyone regardless of their ability to pay, and in fiscal year 2022, provided a net community benefit of approximately $240.3 million in the form of health care for underinsured patients, community education, and financial support to community health organizations in Tampa Bay. It is one of the nation's busiest adult solid organ transplant centers and is the primary teaching hospital for the USF Health Morsani College of Medicine. With five medical helicopters, Tampa General Hospital transports critically injured or ill patients from 23 surrounding counties to receive the advanced care they need. Tampa General houses a nationally accredited comprehensive stroke center, and its 32-bed Neuroscience, Intensive Care Unit is the largest on the West Coast of Florida. It also is home to the Muma Children's Hospital at TGH, the Jennifer Leigh Muma 82-bed neonatal intensive care unit, and a nationally accredited rehabilitation center. Tampa General Hospital's footprint includes TGH North which is comprised of three hospitals and several outpatient locations in Citrus and Hernando counties, 17 Tampa General Medical Group Primary Care offices, TGH Family Care Center Kennedy, TGH Outpatient Center, TGH Virtual Health, and 21 TGH Imaging outpatient radiology centers throughout Hillsborough, Pasco, Pinellas and Palm Beach counties. Tampa Bay area residents also receive world-class care from the TGH Urgent Care powered by Fast Track network of clinics. To see a medical care professional live anytime, anywhere on a smartphone, tablet or computer, visit Virtual Health | Tampa General Hospital (tgh.org). As one of the largest hospitals in the country, Tampa General Hospital is the first in Florida to partner with GE Healthcare and open a clinical command center that provides real-time situational awareness to improve and better coordinate patient care at a lower cost. For more information, go to . ABOUT USF HEALTH USF Health's mission is to envision and implement the future of health. It is the partnership of the USF Health Morsani College of Medicine, the College of Nursing, the College of Public Health, the Taneja College of Pharmacy, the School of Physical Therapy and Rehabilitation Sciences, the Biomedical Sciences Graduate and Postdoctoral Programs, and USF Health's multispecialty physicians' group. The University of South Florida, a high-impact research university dedicated to student success and committed to community engagement, generates an annual economic impact of more than $6 billion. Through hundreds of millions of dollars in research activity each year, USF is a leader in solving global problems and improving lives. For more information, visit health.usf.edu. SOURCE Tampa General Hospital